Kim WJ - Search Results

1

Enhanced expression of peroxiredoxin I and VI correlates with development, recurrence and progression of human bladder cancer.

Quan C, Cha EJ, Lee HL, Han KH, Lee KM, Kim WJ. Quan C, et al. Among authors: kim wj. J Urol. 2006 Apr;175(4):1512-6. doi: 10.1016/S0022-5347(05)00659-2. J Urol. 2006. PMID: 16516038

2

GSTT1-null genotype is a protective factor against bladder cancer.

Kim WJ, Kim H, Kim CH, Lee MS, Oh BR, Lee HM, Katoh T. Kim WJ, et al. Among authors: kim h, kim ch. Urology. 2002 Nov;60(5):913-8. doi: 10.1016/s0090-4295(02)01892-7. Urology. 2002. PMID: 12429337

3

The effect of bone-associated growth factors and cytokines on the growth of prostate cancer cells derived from soft tissue versus bone metastases in vitro.

Lee HL, Pienta KJ, Kim WJ, Cooper CR. Lee HL, et al. Among authors: kim wj. Int J Oncol. 2003 Apr;22(4):921-6. Int J Oncol. 2003. PMID: 12632088

4

Estrogen induction of smooth muscle differentiation of human prostatic stromal cells is mediated by transforming growth factor-beta.

Hong JH, Song C, Shin Y, Kim H, Cho SP, Kim WJ, Ahn H. Hong JH, et al. Among authors: kim h, kim wj. J Urol. 2004 May;171(5):1965-9. doi: 10.1097/01.ju.0000123064.78663.2c. J Urol. 2004. PMID: 15076322

5

Association of bladder tumors and GA genotype of -308 nucleotide in tumor necrosis factor-alpha promoter with greater tumor necrosis factor-alpha expression.

Jeong P, Kim EJ, Kim EG, Byun SS, Kim CS, Kim WJ. Jeong P, et al. Among authors: kim cs, kim eg, kim wj, kim ej. Urology. 2004 Nov;64(5):1052-6. doi: 10.1016/j.urology.2004.06.018. Urology. 2004. PMID: 15533517

6

Genotypes of TNF-alpha, VEGF, hOGG1, GSTM1, and GSTT1: useful determinants for clinical outcome of bladder cancer.

Kim EJ, Jeong P, Quan C, Kim J, Bae SC, Yoon SJ, Kang JW, Lee SC, Jun Wee J, Kim WJ. Kim EJ, et al. Among authors: kim wj, kim j. Urology. 2005 Jan;65(1):70-5. doi: 10.1016/j.urology.2004.08.005. Urology. 2005. PMID: 15667866

7

Genetic and epigenetic aspects of bladder cancer.

Kim WJ, Quan C. Kim WJ, et al. J Cell Biochem. 2005 May 1;95(1):24-33. doi: 10.1002/jcb.20412. J Cell Biochem. 2005. PMID: 15759278 Review.

8

RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors.

Kim WJ, Kim EJ, Jeong P, Quan C, Kim J, Li QL, Yang JO, Ito Y, Bae SC. Kim WJ, et al. Among authors: kim ej, kim j. Cancer Res. 2005 Oct 15;65(20):9347-54. doi: 10.1158/0008-5472.CAN-05-1647. Cancer Res. 2005. PMID: 16230397

9

Impact of obesity in patients with urolithiasis and its prognostic usefulness in stone recurrence.

Lee SC, Kim YJ, Kim TH, Yun SJ, Lee NK, Kim WJ. Lee SC, et al. Among authors: kim yj, kim wj, kim th. J Urol. 2008 Feb;179(2):570-4. doi: 10.1016/j.juro.2007.09.040. Epub 2007 Dec 21. J Urol. 2008. PMID: 18078957

10

Methylation of the RUNX3 promoter as a potential prognostic marker for bladder tumor.

Kim EJ, Kim YJ, Jeong P, Ha YS, Bae SC, Kim WJ. Kim EJ, et al. Among authors: kim yj, kim wj. J Urol. 2008 Sep;180(3):1141-5. doi: 10.1016/j.juro.2008.05.002. Epub 2008 Jul 18. J Urol. 2008. PMID: 18639281

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,108 results

Search Page

Filters